The aim of the study is to elucidate whether guiding by a novel artificial intelligence assisted mobile application can improve the clinical outcomes of patients in whom "guide wire passing through the lesion" could not be achieved within 120 min after diagnosis of STEMI, compared to conventional treatment strategies. With concerns of the inadequate use of thrombolysis in patients with STEMI in China, this study applies a new artificial intelligence assisted mobile application to guide the process of thrombolysis combined with PCI treatment, in order to accomplish the rapid coordination and cooperation of the whole medical network during re-perfusion treatment in different regions and different medical institutions in China, increases the proportion of early thrombolysis in pre-hospital setting, shortens the time from STEMI onset to reperfusion, and provides a reliable, effective and replicable new strategy for promoting and optimizing early reperfusion.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
3,356
A novel artificial intelligence assisted mobile application will be used in the experimental group to guide entire reperfusion process in patients with STEMI. The functions of the application include patient screening, education and training, route planning for patient transfer, time management, and quality control, etc.The thrombolytic drug used in this study is tenecteplase (manufacturer: CSPC Pharmaceutical Group Limited, China ).
No. 83, Wenhua Road, Shenhe District, Shenyang City
Shenyang, Liaoning, China
RECRUITINGIncidence of major adverse events (MAEs) at 1 year
Incidence of major adverse events (MAEs) at 1 year. MAE is a composite endpoint that includes all-cause mortality, stroke, cardiogenic shock, rehospitalization for ischemic heart failure, or reinfarction.
Time frame: Day 365
Total ischemic time before reperfusion
Time frame: Day 30
Total reperfusion rate during therapeutic time window
Time frame: Hour 48
The proportion of ECG ST segment resolution（STR） ≥ 70% after thrombolysis or emergency PCI
Time frame: Hour 48
Proportion of TIMI blood flow grade 3 before emergency PCI
Time frame: Hour 48
Proportion of TIMI blood flow grade 3 after emergency PCI
Time frame: Hour 48
Incidence of 30-day MAEs
MAE is a composite endpoint that includes all-cause mortality, stroke, cardiogenic shock, rehospitalization for ischemic heart failure, or reinfarction.
Time frame: Day 30
Incidence of major adverse cardiac events (MACE) at 1 year
MACE is a composite endpoint including cardiac death, reinfarction, clinically-driven revascularization, ischemic cardiomyopathy, or myocardial ischemia-driven rehospitalization
Time frame: Day 365
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.